Sanuwave Health Stock News

Q1 2025 revenues were $9.3 million , up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history.

EDEN PRAIRIE, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will

SANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest Q1 quarterly revenues in Company history.

SANUWAVE Health, Inc. (NASDAQ:SNWV ) Q4 2024 Results Conference Call March 21, 2025 8:30 AM ET Company Participants Morgan Frank - Chairman and Chief Executive Officer Peter Sorensen - Chief Financial

Q4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company.

Trading Under the Ticker “SNWV” Expected to Begin on March 7, 2025 Trading Under the Ticker “SNWV” Expected to Begin on March 7, 2025

EDEN PRAIRIE, Minn., Feb. 19, 2025 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that Morgan Frank, C

SANUWAVE is pleased to announce preliminary revenues of $10.1 million to $10.3 million for the fourth quarter ended December 31, 2024.  This represents the highest quarterly revenues in company history. Q4 2024 revenue increased between 44% and 47% compared to Q4 2023. UltraMist revenues for Q4 2024 increased by more than 54% versus Q4 2023 and accounted for approximately 98% of the Company’s total revenues. UltraMist applicator sales were an all-time quarterly record and wer...

Wern Brings Strong Team Building, Growth, and Sales Skills to SANUWAVE After a Career of Growing Start Ups Into Mid and Large Sized Companies EDEN PRAIRIE, MN -- January 13, 2025 -- InvestorsHub NewsWire -- SANUWAVE Health, Inc. (the "Company" or " SANUWAVE ") (OTCQB:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Timothy Wern as its Executive Vice President of Sales. Wern brings deep experien...

Q3 2024 revenues were $9.4 million, up 89% from Q3 2023.  This was an all-time quarterly record for the Company.  Q3 2024 gross margin was 75.5%, vs 71.5% in Q3 2023 GAAP Operating Income was $2.0 million Company provides guidance for revenue growth of 40-50% for Q4 2024 versus Q4 2023 EDEN PRAIRIE, MN -- November 8, 2024 -- InvestorsHub NewsWire -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE") (OTCQB: SNWV), a leading provider of next-generation F...

Q3 2024 revenues were $9.4 million, up 89% from Q3 2023. This was an all-time quarterly record for the Company.

EDEN PRAIRIE, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will

1-for-375 reverse stock split effective at market open today Exchanged $43.2 million in principal amount of convertible notes and warrants previously exercisable for approximately 1.7 billion pre-split shares for approximately 4.0 million post-split shares Closed $10.3 million equity only PIPE offering at $8.25 per share of common stock led by certain institutional investors, including AWM Investment Company, Inc., the investment adviser of the Special Situations Funds and with participati...

Common Stock Will Begin Trading on a Split-adjusted Basis on October 18, 2024EDEN PRAIRIE, MN -- October 16, 2024 -- InvestorsHub NewsWire -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE") (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that, effective at 12:01 a.m. Mountain Time on October 18, 2024, the Company will implement a 1-for-375 reverse stock split of its outstanding common stock. The Company's common stock will continue t...

Common Stock Will Begin Trading on a Split-adjusted Basis on October 18, 2024 EDEN PRAIRIE, Minn., Oct. 16, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: